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Abstract
Purpose As people get older, their sensitivity to drugs and
adverse drug reactions can increase due to pharmacokinetic
and pharmacodynamic changes. Older people with dementia
are a particularly vulnerable group of people. They are at an
increased risk of being prescribed potentially inappropriate
medications, which may lead to harmful consequences. The
aim of this study was to investigate the prevalence of poten-
tially inappropriate medications among older patients with
cognitive impairment.
Methods Medical records for patients aged ≥65 years admit-
ted to two hospitals in Northern Sweden were reviewed.
Potentially inappropriate medications were identified using
the EU(7)-PIM list as an identification tool.
Results Of 428 patients included in the study, 40.9% had one
or more potentially inappropriate medication prescribed. The
most commonly represented potentially inappropriate medi-
cation classes were hypnotics and sedatives, cardiovascular
drugs and laxatives. The most commonly involved potentially
inappropriate medications were zopiclone, digoxin and sodi-
um picosulfate. There was an association seen between having
a higher number of medications prescribed and having one or
more potentially inappropriate medication.
Conclusion Potentially inappropriate medications are preva-
lent among older people with cognitive impairment living in
Northern Sweden. It is important to continuously evaluate the
need for potentially inappropriate medications in this patient
group, in order to prevent adverse drug reactions, especially
among those who have a higher number of medications
prescribed.
Keywords Older people . Cognitive impairment . Potentially
inappropriate medications . EU(7)-PIM list
Introduction
Drugs are a keystone in the treatment of chronic conditions
among the elderly [1], and old people are at increased risk of
being exposed to polypharmacy [2]. However, the prescrip-
tion of certain drugs, potentially inappropriate medications
(PIMs), may expose this group of people to an increased risk
of experiencing adverse drug reactions (ADRs) [3–5]. The
higher risk of experiencing ADRs is due to the physiological
changes that occur in the body as people get older [6]. People
with cognitive impairment are even more vulnerable to ADRs
than those without cognitive impairment due to the neuro-
chemical changes in neurotransmitter substances that occur
especially in people with dementia [1]. The ADRs may also
occur at a higher frequency, and to a higher degree, among this
patient group [1, 6], and it is seen that the risk of experiencing
ADRs increases among old people (OR 1.59, 95% CI 1.10–
2.29) [7].
One definition of PIM is Bthose drugs which should not be
prescribed for this population because the risk of adverse
events outweighs the clinical benefit, particularly when there
is evidence in favour of a safer or more effective alternative
therapy for the same condition^ [4]. PIMs such as antipsy-
chotics and other psychotropic drugs are commonly pre-
scribed in order to treat symptoms due to dementia, even
though these drugs are associated with severe ADRs [3,
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8–10]. It is also seen that people with dementia on average
take more medications compared to people without dementia
[11]. Antipsychotics and some antidepressants may give pe-
ripheral anticholinergic and CNS side effects, e.g. sedation,
confusion and impairment of cognitive ability due to the re-
duction of acetylcholine levels in older people [3, 4].
Anticholinergic agents are especially associated with negative
outcomes such as risk of falls, delirium, increased mortality
and cognitive impairment [5]. Agents such as anxiolytics,
hypnotics and sedatives increase the risk of falling, with hip
fracture as a possible outcome. Furthermore, anti-
inflammatory and antirheumatic drugs may increase the risk
of gastroduodenal bleeding and ulceration among older peo-
ple [4].
There has been—and still is—an ongoing debate in society
about the use of PIMs among older people due to the higher
frequency and degree of ADRs experienced [3–5]. Studies
investigating PIM use among older people show that older
people living in nursing homes had PIMs more often com-
pared to those living in their homes [12, 13]. Prescribing
habits of doctors may differ and there may be a different pre-
scribing culture depending on where in the country they are
practising. This may result in a different prevalence of PIM
use depending on where the patients live [14].
Up until now, only evaluation tools developed following
country-specific guidelines have been available in order to
identify PIM use [4]. For example, Beers Criteria are one of
the most commonly used instruments for the evaluation of
PIM use among older people [15]. However, the use of med-
ications differs significantly between Europe and the USA,
which has hampered the use of these criteria in Europe [15,
16]. STOPP criteria are another well-used evaluation tool.
Unlike Beers List, STOPP criteria reflect European prescrib-
ing patterns, but clinical information about the patients’ health
status is required in order to make a correct evaluation of the
PIM use [4, 17, 18]. In May 2015, an explicit European PIM
list, the European Union (EU)(7)-PIM list, was established in
order to identify and compare prescribing patterns of PIMs for
older people within and between European countries. This list
may also be used in clinical practice in order to make more
suitable choices of medicines even though it does not substi-
tute an individual decision-making. Experts from seven
European countries developed this expert-consensus list tak-
ing into consideration medications included in six country-
specific PIM lists and additional medications used in seven
European countries. A preliminary PIM list was first devel-
oped. A structured expansion of the list was then performed
before a two-rounded Delphi survey, and a final survey was
made, which finally resulted in the establishment of the
EU(7)-PIM list [4, 19].
Older people with cognitive impairment are particularly
vulnerable to drug effects and ADRs, and it is seen that hos-
pital admissions among this patient group are often due to
ADRs [3, 7, 20]. It is therefore important to identify and pay
attention to PIM use in order to improve the drug use among
this vulnerable group of people. To our knowledge, no study
has been conducted with the EU(7)-PIM list as an identifica-
tion tool, to identify prescribing patterns of PIM among older
people with cognitive impairment.
The aim of this study was therefore to establish the preva-
lence of PIMs among older people, aged ≥65 years, with cog-
nitive impairment admitted to two hospitals in Northern
Sweden between January 9, 2012 and December 2, 2014,
using the EU(7)-PIM list as an identification tool. A secondary
objective was to investigate factors associated with the use of
PIM.
Method
Settings and study design
This study, which was a cross-sectional study, used data
collected for a randomized controlled intervention study
conducted between January 9, 2012 and December 2,
2014, at Norrland’s University Hospital and the county
hospital of Skellefteå (Gustafsson M et al. (2016), unpub-
lished observations). The purpose of the intervention was
to investigate if drug-related problems (DRPs) and
readmissions were reduced when a pharmacist conducted
medication reviews as part of a healthcare team. Baseline
data from the intervention study was used in the present
study. Both intervention and control persons were there-
fore treated as one homogenous study sample. Patients,
65 years and older with dementia or cognitive impair-
ment, admitted to the acute internal medicine ward or
the orthopaedic ward at Norrland’s University Hospital
or to a medical ward at the county hospital of Skellefteå
were recruited. Medical records were carefully reviewed
before inclusion. Dementia diagnoses were collected from
the medical record. Patients were considered to have cog-
nitive impairment if sufficient information in the medical
record related to memory, orientation or executive func-
tion was noted before hospitalization. In addition, patients
in whom dementia was suspected and medical investiga-
tion had been commenced or would be initialized were
included. In ambiguous or uncertain cases, patients were
excluded. The procedure described was chosen to avoid
the risk of including persons without dementia or cogni-
tive impairment who had developed a delirious or con-
fused state during the hospital stay.
The study sample comprises 460 people with dementia or
cognitive impairment. People who died during a hospital stay
(31 people) and people who withdrew from the intervention
study during a hospital stay (1 person) were excluded. The
final sample was 428 people.
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Data extraction
The medications and doses that the person used at admission
to the hospital wards were collected from the persons’medical
records. Age, sex, type of accommodation and geographic
location were also collected from the persons’ medical re-
cords. Prescriptions with pro re nata dose (oxazepam,
nabumeton, hydroxyzin, diazepam, alimemazin) were not in-
cluded in the analysis due to uncertainty about the patients
use. Over-the-counter drugs were not included in the analysis
due to lack of information about their use.
Definitions
PIMs were identified using the EU(7)-PIM list [4]. This
complete list comprises 282 drug substances (n = 275) or
drug classes (n = 7) classified as PIMs. Drugs that were
defined as treatment duration-dependent PIMs according
to the EU(7)-PIM list (PPI (omeprazole, pantoprazol,
lansoprazol, rabeprazol, esomeprazole), bisacodyl,
loperamid, nitrofurantoin, ibuprofen, naproxen, risperi-
done and codeine) and regimen-dependent PIMs accord-
ing to the same list (insulin, sliding scale) were all ex-
cluded due to lack of information in medical records.
Formulations designed for local administration (e.g.
diclofenac gel) were excluded as well. Also, drugs not
approved for the Swedish market were excluded. Thus,
of the 282 substances or drug classes, 137 substances
were selected for the current analysis (Appendix 1).
Data analysis
Descriptive statistics were used to summarize the data.
Frequencies were calculated for dichotomous variables
such as sex, type of accommodation (living in their home
or in a nursing home) and geographic location (Skellefteå
or Umeå). The continuous variables age, number of med-
ications at admission and Mini-Mental Stage Examination
(MMSE) result were presented as mean values with stan-
dard deviation (SD).
Simple logistic regression analyses were conducted to in-
vestigate the association between people with and without
PIMs and factors extracted from the medical record. The ex-
tracted factors included in the analysis were sex, age, number
of medications at admission, MMSE, type of accommodation
and geographic location. A multiple logistic regression anal-
ysis was conducted including age, sex and significant vari-
ables from the simple model.
Results are presented as odds ratios with 95% confidence
intervals.
All analyses were conducted using IBMSPSS Statistics 22.
Results
Of 428 people in the study sample, 175 (40.9%) had one or
more PIMs; 130 (30.4%) had one PIM, 39 (9.1%) had two
PIMs and 6 (1.4%) had three PIMs. Among the study sample,
270 (63.1%) were women. No significant association between
gender and PIMs was seen. Mean age and mean MMSE were
83.2 ± 6.6 years and 19.8 ± 4.6, respectively. No significant
association was seen between age and having one or more
PIMs. The mean number of medications at admission was
7.8 ± 3.5. A significant association was seen between having
a higher number of medications prescribed at admission and
having one or more PIMs. Moreover, 131 (30.6%) people had
Alzheimer’s disease and 72 (16.8%) had vascular dementia,
but other or unspecified dementia was the most common type
of dementia [n = 225 (52.6%)]. Living at home was the most
common type of accommodation [n = 304 (71.0%)], and most
people in the study sample were admitted to the hospital wards
in Umeå [n = 321 (75.0%)] (Table 1).
Of the 137 PIMs in the list, 52 (38.0%) were found among
the study sample. Further, 6.8% (226/3317) of all prescrip-
tions were identified as PIMs among the analysed medical
records. The three most commonly represented PIM classes
among the identified prescriptions were hypnotics and seda-
tives (ATC code N05C) [n = 57 (25.2%)], cardiac therapy
(C01) [n = 36 (15.9%)] and laxatives (A06A) [n = 19
(8.4%)]. The most commonly involved PIMs were zopiclone
[n = 39 (17.3%)], digoxin [n = 33 (14.6%)] and sodium
picosulfate [n = 19 (8.4%)] (Table 2).
Discussion
The prevalence of PIMs (41%) in the study population is in
line with or somewhat higher than that reported previously
among people with dementia. Prevalences between 15 and
46.8% have been reported when Beers List, STOPP criteria
or the Laroche list were used as identification tools [10, 11,
16–18, 21–24].
The high use of PIMs among this study population war-
rants concern. The use of PIMs might result in drug-related
morbidity andmay also contribute to hospital admissions [20].
One study investigating the proportion of drug-related admis-
sions among the same population as in the present study
showed that 41% were judged to be drug related [20].
Inappropriate drug use accounted for 10.6% of these drug-
related admissions, and even if other criteria for inappropriate
drugs were used in that study, it still shows the importance of
carefully considering prescribing PIMs among older people
with dementia.
Both univariate and multivariate analysis showed that pa-
tients with a higher number of medications were more likely to
have PIMs in the present study. This is consistent with the
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results of other studies including older people with dementia
[11, 18, 23]. Having a higher number of medications prescribed
may indicate multiple comorbidities and therefore an increased
risk of being prescribed PIMs for diseases, experienced symp-
toms or, in the worst case, undetected ADRs, a risk that in-
creases as the number of prescribed drugs increases. ADRs
may be hard to detect and may be mistaken as symptoms to
treat. Interactions and non-adherence are other risk factors that
may have harmful consequences among older patients with
dementia, which are linked to a high number of prescribed
medications [25]. It is therefore important to continuously take
a patient’s clinical conditions into consideration, put the medi-
cine use into perspective and carry out a careful risk-benefit
evaluation when consider prescribing PIMs [4].
There was no association between gender and PIMs seen in
the present study. Previous research shows inconsistent results
[18, 23]. Further, no association was seen between age and
having PIMs. These results were also seen in another study by
Parsons et al. [18]. PIM use among people living in nursing
homes has been found to be more common than among those
living in their homes according to previous research [12, 13].
However, this was not found in the present study. Also, no
association between having PIMs and geographic location
was found. Overall, the present results indicate that the focus
on prescribing pattern should be directed towards older people
with dementia regardless of their age, gender or where they
live.
Hypnotics and sedatives were the most common type of
PIM class prescribed in the present study, and the prevalence
is almost twice as high compared to another study [22]. The
number of people prescribed this PIM class was also higher in
the present study compared to other studies [23, 24]. Zopiclone
was the most commonly prescribed drug among PIMs for hyp-
notics and sedatives. A probable reason for the high level of
zopiclone prescribing is that this drug is the first-line sedative
recommended among older people in Sweden, but only for a
short period of time, ≤30 days, with a maximum daily dose of
7.5 mg [25]. According to the EU(7)-PIM list, the maximum
daily dose of zopiclone is 3.75 mg [4]. However, it is important
to remember the potential side effects of zopiclone, such as falls
with hip fractures as a possible outcome. Other side effects that
may arise when using zopiclone are psychiatric reactions and
impairment of cognitive function [25]. Propiomazin was also
prevalent among the identified prescriptions. Propiomazin is a
drug that should be prescribed with caution due to its risk of
prolonged sedation and extrapyramidal side effects within older
people [4, 25]. Further, the EU(7)-PIM list states that
flunitrazepam and nitrazepam should be used with caution in
older people, consistent with the Swedish guidelines, due to the
risk of falling [4, 25]. Fortunately, the prevalence of these PIMs
was low in the present study. The sleep pattern changes with
age and insomnia are a common problem among older people.
Dementia and depression may be other reasons for having dif-
ficulty sleeping [26]. This may be another reason for the high
prescribing frequency of sedatives [27]. It is important, though,
to treat the true cause and not the experienced symptoms [1].
Digoxin represented the highest prescribing frequency
among PIMs for cardiac therapy, with nearly one in five pa-
tients being prescribed this drug. Digoxin accumulation and
elevated sensitivity to glycosides may lead to intoxication
within older people due to changes in pharmacokinetic and
pharmacodynamic parameters. It is therefore important to
continuously evaluate the serum concentration of this drug
[4].
Table 1 Characteristics of study population and comparison between people with and without PIMs
Characteristics of study sample Total PIM(s) No PIM Simple OR (95% CI) Multiple OR (95% CI)
Cases, n 428 175 253
Gender, n (%)
Female 270 (63.1) 113 (64.6) 157 (62.1) 1.114 (0.747-1.663) 1.116 (0.720–1.730)
Male 158 (36.9) 62 (35.4) 96 (37.9) Ref
Age (years), mean ± SD (range) 83.2 ± 6.6 (65–99) 83.0 ± 6.8 83.3 ± 6.4 0.993 (0.964–1.022) 0.995 (0.964–1.028)
Number of medications at admission, mean ± SD (range) 7.8 ± 3.5 (0–20) 9.3 ± 3.1 6.7 ± 3.4 1.281 (1.197–1.370) 1.281 (1.197–1.370)
MMSE (0–30), mean ± SD (range) 19.8 ± 4.6 (7–29) 19.7 ± 4.3 19.9 ± 4.8 0.990 (0.923–1.063) -
Type of accommodation, n (%)
Nursing home 124 (29.0) 59 (33.7) 65 (25.7) 1.471 (0.965–2.243) -
Living at home 304 (71.0) 116 (66.3) 188 (74.3) Ref
Geographic location, n (%)
Skellefteå 107 (25.0) 50 (28.6) 57 (22.5) 1.375 (0.885–2.138) -
Umeå 321 (75.0) 125 (71.4) 196 (77.5) Ref
The multiple analyses include sex, age and significant variables from the simple model (number of medications at admission)
CI confidence interval, MMSEMini-Mental Stage Examination, OR odds ratio, PIM(s) potentially inappropriate medication(s), SD standard deviation
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Table 2 Prescribing frequency and frequency of affected patients for each identified PIM
ATC code Drug class/name Prescriptions, n (col %) Patients, n (col %) 175
A02 Drugs for acid-related disorders 2 (0.9) 2 (1.1)
Aluminium-containing antacids (A02AD01) 1 (0.4) 1 (0.6)
Ranitidine (A02BA02) 1 (0.4) 1 (0.6)
A03F Drugs for functional gastrointestinal disorders—propulsives 3 (1.3) 3 (1.7)
Metoclopramide (A03FA01) 3 (1.3) 3 (1.7)
A06A Laxatives 19 (8.4) 19 (10.9)
Sodium picosulfate (A06AB08) 19 (8.4) 19 (10.9)
A10B Blood glucose-lowering drugs, excl. insulins 16 (7.1) 16 (9.1)
Glibenclamide (A10BB01) 8 (3.5) 8 (4.6)
Glimepiride (A10BB12) 1 (0.4) 1 (0.6)
Glipizide (A10BB07) 7 (3.1) 7 (4.0)
B01A Antithrombotic agents 6 (2.7) 6 (3.4)
Dabigatran (B01AE07) 2 (0.9) 2 (1.1)
Dipyridamole (B01AC07) 4 (1.8) 4 (2.3)
C01 Cardiac therapy 36 (15.9) 36 (20.1)
Digoxin (C01AA05) 33 (14.6) 33 (18.9)
Amiodarone (C01BD01) 2 (0.9) 2 (1.1)
Ivabradine (C01EB17) 1 (0.4) 1 (0.6)
C02 Antihypertensives 4 (1.8) 4 (2.3)
Doxazosin (C02CA04) 3 (1.3) 3 (1.7)
Hydralazine (C02DB02) 1 (0.4) 1 (0.6)
C03D Diuretics—potassium-sparing agent 5 (2.2) 5 (2.9)
Spironolactone (>25 mg/day) (C03DA01) 5 (2.2) 5 (2.9)
C07A Betablocking agents 3 (1.3) 3 (1.7)
Pindolol (C07AA03) 2 (0.9) 2 (1.1)
Propranolol (C07AA05) 1 (0.4) 1 (0.6)
C08 Calcium channel blockers 4 (1.8) 4 (2.3)
Nifedipine (C08CA05) 1 (0.4) 1 (0.6)
Diltiazem (C08DB01) 2 (0.9) 2 (1.1)
Verapamil (C08DA01) 1 (0.4) 1 (0.6)
G03C Oestrogens 6 (2.7) 6 (3.4)
Estriol (oral) (G03CA04) 6 (2.7) 6 (3.4)
G04B Other urologicals, incl. antispasmodics 12 (5.3) 12 (6.9)
Darifenacin (G04BD10) 1 (0.4) 1 (0.6)
Fesoterodin (G04BD11) 1 (0.4) 1 (0.6)
Solifenacin (G04BD08) 6 (2.7) 6 (3.4)
Tolterodine (G04BD07) 4 (1.8) 4 (2.3)
M01A Anti-inflammatory and antirheumatic products—NSAID (oral) 3 (1.3) 3 (1.7)
Diclofenac (M01AB05) 1 (0.4) 1 (0.6)
Ketoprofen (M01AE03) 2 (0.9) 2 (1.1)
M03B Muscle relaxants—centrally acting agents 1 (0.4) 1 (0.6)
Orphenadrine (M03BC01) 1 (0.4) 1 (0.6)
N02A Analgesics—opioids 4 (1.8) 4 (2.3)
Tramadol (N02AX02) 4 (1.8) 4 (2.3)
N03A Antiepileptics 10 (4.4) 10 (5.7)
Carbamazepine (N03AF01) 7 (3.1) 7 (4.0)
Clonazepam (N03AE01) 2 (0.9) 2 (1.1)
Phenytoin (N03AB02) 1 (0.4) 1 (0.6)
N04 Antiparkinson drugs 5 (2.2) 5 (2.9)
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The third highest prescribed PIM class in the present study
was laxatives, with one in ten of the patients having had sodi-
um picosulfate prescribed. Due to the risk of, e.g. abdominal
pain, fluid and electrolyte imbalance and exacerbation of bow-
el dysfunction, it is only recommended to be used periodically
[4]. However, a pro re nata dose may result in non-adherence
among older patients with dementia. It may therefore be rec-
ommended for regular use, which complicates the situation
and exposes an already vulnerable group of people to in-
creased risks of experiencing ADRs. Preferably, osmotically
active agents such as macrogol or lactulose should be used
instead [4].
Additionally, blood glucose-lowering drugs were among
the most commonly prescribed PIM classes. This PIM group
comprises the following sulfonurides: glibenclamide,
glimepiride and glipizide. Particular caution is required with
these PIMs due to the risk of hypoglycaemia among older
people, which may have particularly harmful consequences
in older people with dementia [28]. Other PIMs prevalent
among the prescriptions were solifenacin and tolterodine,
which are worth mentioning due to their anticholinergic side
effects. These PIMs may exacerbate the people’s cognitive
status, increase the risk of falls and cause delirium, sedation
and increased mortality [3–5].
Different prescribed PIMs and PIM classes are prevalent to
different degrees when comparing studies. Some studies state
that neuroleptics, long-term antipsychotics, anticholinergics
and oral oestrogens are the most commonly prescribed PIM
classes among older people with dementia [11, 17, 18, 21–24].
The most commonly prescribed PIMs in other studies are
oxybutinin, nifedipine, fluoxetine and tolterodine [11, 21,
22, 24]. The reasons for different prevalences and different
PIMs may be that the drugs are prescribed in different ways
depending on the current prescribing recommendations and
the cost of medicines, but this also depends on which screen-
ing tools have been used. The EU(7)-PIM list is deemed to be
a sensitive identification tool, which may explain the higher
prevalence of PIMs identified in the present study [4].
Compared to current Swedish guidelines, the EU(7)-PIM list
recommends lower maximum doses, regarding for example
zopiclone [4, 19]. The utilization of the EU(7)-PIM list in
clinical practice may therefore further prevent the negative
Table 2 (continued)
ATC code Drug class/name Prescriptions, n (col %) Patients, n (col %) 175
Pramipexole (N04BC05) 3 (1.3) 3 (1.7)
Trihexyphenidyl (N04AA01) 2 (0.9) 2 (1.1)
N05A Antipsychotics 7 (3.1) 7 (4.0)
Clozapine (N05AH02) 1 (0.4) 1 (0.6)
Haloperidol (>2 mg single dose; >5 mg/day) (N05AD01) 2 (0.9) 2 (1.1)
Lithium (N05AN01) 2 (0.9) 2 (1.1)
Perphenazine (N05AB03) 2 (0.9) 2 (1.1)
N05B Anxiolytics 5 (2.2) 5 (2.9)
Alprazolam (N05BA12) 5 (2.2) 5 (2.9)
N05C Hypnotics and sedatives 57 (25.2) 57 (32.6)
Clomethiazole (N05CM02) 3 (1.3) 3 (1.7)
Flunitrazepam (N05CD03) 2 (0.9) 2 (1.1)
Nitrazepam (N05CD02) 1 (0.4) 1 (0.6)
Propiomazine (N05CM06) 10 (4.4) 10 (5.7)
Triazolam (N05CD05) 1 (0.4) 1 (0.6)
Zolpideme (>5 mg/day) (N05CF02) 1 (0.4) 1 (0.6)
Zopiclone (>3.75 mg/day) (N05CF01) 39 (17.3) 39 (22.3)
N06A Antidepressants 15 (6.6) 15 (8.6)
Amitryptiline (N06AA09) 7 (3.1) 7 (4.0)
Bupropion (N06AX12) 1 (0.4) 1 (0.6)
Paroxetine (N06AB05) 2 (0.9) 2 (1.1)
Venlafaxine (N06AX16) 5 (2.2) 5 (2.9)
R03D Other systemic drugs for airway diseases 1 (0.4) 1 (0.6)
Theophylline (R03DA04) 1 (0.4) 1 (0.6)
R06A Antihistamines for systemic use 2 (0.9) 2 (1.1)
Clemastine (R06AA04) 2 (0.9) 2 (1.1)
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consequences and the risk of experiencing ADRs. An advan-
tage of the EU(7)-PIM list is also that alternatives to PIMs are
suggested that may be more appropriate to prescribe to this
vulnerable group of people.
There are some limitations with the present study. The
EU(7)-PIM list is relatively new and may be further revised
[4]. Only about half of the EU(7)-PIM list was evaluated in the
present study because many drugs are not approved on the
Swedish market. Also, duration and regimen-dependent
PIMs and prescriptions with a pro re nata dose were excluded,
which may lower the prevalence of PIMs among the study
population. It is also impossible to draw conclusions about
the negative outcomes of PIM use, e.g. ADRs, or the quality
of prescribing within the present study population because of
the cross-sectional study design and the explicit criterion used.
Strengths with the present study include the fact that the
results of this study are representative for people aged 65 years
or older with dementia or cognitive impairment, since no other
inclusion or exclusion criteria were used. Also, out of 473
invited patients, only 13 declined participation. Medication
records utilized in the present study are also a reliable source
of information [29]. The EU(7)-PIM list is a European guide-
line, which makes the present result internationally compara-
ble among different European countries. Additionally, the
present study is, as far as we know, the first to utilize the
EU(7)-PIM list as an identification tool of PIMs among older
people with cognitive impairment.
Conclusion
PIMs are prevalent among older people with cognitive impair-
ment and dementia living in Northern Sweden. It is important
to continuously evaluate the need for PIMs in order to prevent
ADRs, especially among people who have a higher number of
medications prescribed. Assessment tools are being used in-
creasingly for the evaluation of prescribing quality in older
people, but their application cannot substitute the individual
assessment of prescribing appropriateness.
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